Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Elanix Signs Supply and Manufacturing Agreements with Sincopharm and Tec-Pharma for Production of Medical Cosmetics Acquired from Repair-A

Elanix Biotechnologies AG
Posted on: 10 Oct 16

Elanix Biotechnologies AG (FSE:ELN), a developer of tissue regeneration products, announced today the signing of supply agreements with two Swiss companies, Sincopharm SA and Tec-Pharma SA. The agreements will assure manufacturing sustainability at high quality and supply reliability of two commercially available medical cosmetic products, to alleviate gynecological and dermatological conditions, obtained from the recent acquisition of Repair-A SA.

Elanix now has complete control of the formulation, production and commercialization worldwide for the two progenitor cell-based products GynRepair, a treatment for vulvodynia and RepAir-A, a dermatological used to rejuvenate the skin following damage. Elanix anticipates significant sales growth for these products in the next 12 months through combination of direct and distributor sales initially in Switzerland and Europe.

“These agreements allow Elanix to ensure our customers continue to have access to these innovative products. There is significant demand for effective and proven medical cosmetics, and we are now uniquely placed to access these growing markets,” Tomas Svoboda, CEO, Elanix Biotechnologies AG stated. “Our OTC division, headed by Bruno Tenaille, will now begin to roll out a comprehensive marketing and sales strategy to reach as many existing and new customers as possible.”

Both based in Switzerland, Sincopharm SA is dedicated to development and manufacturing of cosmetic formulations. It was established in 1989 by two pharmacists Pierre and Christian Aubort. Tec-Pharma SA is a cosmetic developer and manufacturer of biological actives for a range of applications for both human and veterinary use.

Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.

The Company is headquartered in Nyon, Switzerland with offices in Potsdam and listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit

Disclaimer / Forward-looking statements:

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

View source version on

Business Wire

Last updated on: 10/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.